Bicara Therapeutics (BCAX) EBITDA (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of EBITDA data on file, last reported at -$56.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 53.88% year-over-year to -$56.7 million; the trailing twelve-month figure through Mar 2026 stood at -$162.2 million (down 70.66% YoY), and the FY2025 full-year result was -$137.7 million, down 102.53% from the prior year.
• EBITDA for Q1 2026 stood at -$56.7 million, down from -$37.0 million in the prior quarter.
• Across five years, EBITDA topped out at -$9.5 million in Q3 2023 and bottomed at -$56.7 million in Q1 2026.
• The 4-year median for EBITDA is -$21.0 million (2024), against an average of -$26.9 million.
• The widest annual swing landed in 2024, when EBITDA sank 53.12%; it then slumped 139.66% in 2025.
• A 4-year view of EBITDA shows it stood at -$13.7 million in 2023, then slumped by 53.12% to -$21.0 million in 2024, then plunged by 76.59% to -$37.0 million in 2025, then slumped by 53.21% to -$56.7 million in 2026.
• The last three EBITDA figures came in at -$56.7 million (Q1 2026), -$37.0 million (Q4 2025), and -$36.5 million (Q3 2025), per Business Quant data.

Peer Comparison